Genus
GNS · Main Market · Health Care · mcap £1,490m · 2272.0p
Answered by AI only from GNS’s own announcements, every statement linked to its source. Free with an account – no password, just a link. Not investment advice.
- Market cap
- £1.5bn
- EV
- £1.3bn
- Net debt
- £37.6m
- Revenue
- £658m
- Adj. EBITDA
- £131m
- Shares
- 66.3m −0.4%
-
9 Oct
Annual Report and Annual General Meeting
Genus plc (LSE: GNS) announces that the following documents have been sent to shareholders:
-
10 Sep
Share Buyback Programme
Genus (LSE: GNS; the “Group” or the “Company”), a global leader in animal genetics, announces that it is commencing a share buy-back programme (the “Programme”) pursuant to...
-
10 Sep
Final Results
Preliminary results for the year ended 30 June 2026
-
14 Jul
FY26 Trading Update – Ahead of expectations
Genus (LSE: GNS), a leading global animal genetics company, publishes the following unaudited trading update for the year ended 30 June 2026 ("FY26").
-
4 Mar
Director Declaration
Genus plc (LSE: GNS) today announces that Lysanne Gray, Non-Executive Director, has been appointed as a Non-Executive Director of Johnson Service Group plc, a FTSE 250 listed...
Company filings. Not investment advice.